Xenon Pharmaceuticals (XENE) Set to Announce Earnings on Thursday

Xenon Pharmaceuticals (NASDAQ:XENE) is scheduled to be releasing its earnings data after the market closes on Thursday, August 8th. Analysts expect Xenon Pharmaceuticals to post earnings of ($0.72) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.07. The business had revenue of $1.00 million for the quarter. During the same quarter in the prior year, the business posted ($0.63) EPS. The business’s quarterly revenue was up .0% compared to the same quarter last year. On average, analysts expect Xenon Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Xenon Pharmaceuticals Price Performance

Shares of Xenon Pharmaceuticals stock traded up $1.09 during trading on Tuesday, hitting $42.57. 90,921 shares of the company’s stock traded hands, compared to its average volume of 405,885. The firm’s fifty day moving average price is $39.53 and its 200 day moving average price is $42.37. Xenon Pharmaceuticals has a twelve month low of $27.99 and a twelve month high of $50.99. The company has a market cap of $3.21 billion, a PE ratio of -15.45 and a beta of 1.26.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday, April 10th. Citigroup decreased their target price on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, June 18th. Wedbush cut their price target on shares of Xenon Pharmaceuticals from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, May 10th. Finally, Needham & Company LLC reissued a “buy” rating and set a $62.00 price target on shares of Xenon Pharmaceuticals in a report on Friday, May 10th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.11.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.